Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexamethasone vs Prednisone (with Melphalan) in Untreated Symptomatic Multiple Myeloma
NCT00002678Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 1995
- Primary completion
- May 2004
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised trial of dexamethasone in multiple myeloma (MM) (4 arms), sponsored by Canadian Cancer Trials Group. Primary endpoint: Overall Survival at 9 years. Started Jun 1995; status: completed.
02
Drugs
dexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00002678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002678.